D-Kd for RRMM: MMY1001 final analysis
Sagar Lonial, MD, FACP, Winship Cancer Institute at Emory University, Atlanta, GA, discusses the final analysis of a phase 1b…
Related Articles
The importance of the MDT to provide adequate treatment and care to patients with amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, emphasizes the importance of using a multidisciplinary team (MDT) in the care of patients…
Insights into the treatment and management of BPDCN: CD123-targeted agents & combination therapy
VJHemOnc is pleased to share a feature article which explores treatment approaches for BPDCN. This article covers promising new therapies, drawing focus on the role of…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
VJHemOnc – The video journal of hematological oncology
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
Practical advice for the management of patients with CML who are pregnant or wish to conceive
Elisabetta Abruzzese, MD, PhD, S. Eugenio University Hospital, Rome, Italy, summarizes her talk on fertility and pregnancy in patients with chronic myeloid leukemia (CML). Current…
The Chronic Lymphocytic Leukemia (CLL) Channel – VJHemOnc
Explore the latest Chronic Lymphocytic Leukemia (CLL) updates, including expert interviews, features, podcasts and e-learning on the VJHemOnc CLL Channel
The evolving use of selinexor in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the use of selinexor in the treatment of multiple myeloma,…
Treatment schedule for ruxolitinib in patients with MPNs and how to assess response
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, outlines the treatment schedule for ruxolitinib in patients with myeloproliferative neoplasms (MPNs) and discusses how to assess if…
Shaping the future of medicine · 24.–25. September 2024 Leipzig
stfom.com Shaping the future of medicine · 24.–25. September 2024 Leipzig
Insights into the management of MDS/MPN overlap syndromes & advice for clinicians
Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, discusses the current approach to managing myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes, which focuses on symptom-directed therapy.…